Re: What's the deal with Zenith?
in response to
by
posted on
Jun 23, 2023 10:24AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Buckeyes - Don't get me wrong, I'm a very big believer in the science of both companies, always have been. The potential is out of this world. Eversana sees the potential as well. Just look at the valuations I've come up with over the last six years or so on this board to see what I think the potential of ABL is. It makes DM's conservative value of sales of $8 billion a year look like child's play.
This whole string started because I said Payzone was correct in sharpening his/her pencil and I'll stand by that comment. When I first got involved in this story about 13 years ago there was less than 40 million shares outstanding, there is a few more than that outstanding today. I'm just saying go into this with both eyes open.
tada